The new study, published in the British Journal of Cancer, focuses on a kinase called ATR, short for ataxia telangiectasia and Rad3-related protein. ATR sits at the heart of the cellular response to replication stress, the potentially lethal situation in which the molecular machinery that copies DNA stalls or breaks down. When chemotherapy drugs such as mitomycin C damage DNA, dividing cells rely heavily on ATR signalling to pause the cell cycle, stabilise stalled replication forks and coordinate repair. Block ATR pharmacologically, and cells exposed to DNA-damaging agents lose their safety net: replication forks collapse, DNA double-strand breaks accumulate, and the cell is pushed toward catastrophe. This concept, often described as exploiting a vulnerability created by the tumour’s own dependence on DNA damage checkpoints, has already shown promise in clinical trials of ATR inhibitors such as berzosertib in combination with platinum chemotherapy for advanced solid tumours.

What makes the Utrecht study distinctive is its model system. Rather than relying on immortalised cancer cell lines grown in two dimensions, which often fail to capture the biology of real tumours, the team used patient-derived organoids, miniature three-dimensional tumour cultures grown from tissue of six patients with non-muscle invasive bladder cancer. Organoids preserve many of the genetic and molecular features of the original tumours, including the expression of urothelial carcinoma markers, making them a far more faithful testing ground for new drug combinations. The researchers confirmed that their organoid lines expressed characteristic bladder cancer markers, validating them as genuine representatives of the disease they were designed to model.

The experimental design cleverly mimicked clinical practice. In patients, mitomycin C is delivered directly into the bladder as an instillation that remains in contact with the tumour tissue for roughly one to two hours before being drained. The researchers therefore exposed the organoids to mitomycin C for just two hours, replicating the transient exposure that tumour cells experience in the bladder, and only afterwards did they add ATR inhibitors, which the cells encountered for a prolonged 72-hour period. Three clinically relevant ATR inhibitors were tested: berzosertib, ceralasertib and tuvusertib, all of which have entered clinical trials in various cancers. The team also examined combinations with gemcitabine and epirubicin, two further agents used in intravesical chemotherapy regimens, in one organoid line.

The results were striking. Organoids treated with mitomycin C alone, or with an ATR inhibitor alone, eventually recovered: when the researchers followed the cultures for six weeks after treatment, the surviving cells proliferated at rates similar to untreated controls, demonstrating that neither agent on its own could eliminate the tumour cell population. In sharp contrast, organoids that received the sequential combination of mitomycin C followed by an ATR inhibitor showed severely impaired viability, and crucially, this effect persisted throughout the six-week observation period. The combination did not merely slow the cancer cells down; it appeared to destroy their capacity to regrow, which is precisely the property needed for a therapy intended to prevent recurrence after tumour resection.

Delving into the mechanism, the researchers showed that berzosertib potently suppressed the ATR signalling that mitomycin C normally triggers. DNA damage induced by the chemotherapy was marked by phosphorylated H2AX, a well-established molecular beacon of DNA double-strand breaks, and blocking ATR prevented the checkpoint response that would normally allow cells to survive this damage. Consistent with catastrophic, irreparable DNA damage, the combination treatment drove the organoid cells into apoptosis, the controlled programme of cell death. Quantitative analysis of the drug interaction using synergy scoring frameworks confirmed that the effect was genuinely synergistic rather than merely additive, meaning the two drugs together killed far more cells than would be predicted from their individual activities.

The implications for patients are considerable. Recurrence after intravesical therapy remains the central clinical challenge in non-muscle invasive bladder cancer, driving repeated surgeries, lifelong surveillance and, in a substantial minority of cases, progression to life-threatening muscle-invasive disease. The economic burden of bladder cancer across Europe is among the highest of any malignancy, largely because of the intensity of monitoring and repeat treatment that recurrence entails. A regimen that converts transient chemotherapy exposure into durable eradication of residual tumour cells could reduce recurrence rates, spare patients repeated interventions and delay or prevent progression. Because ATR inhibitors such as berzosertib, ceralasertib and tuvusertib are already in clinical development, the path from laboratory finding to clinical testing is shorter than for an entirely novel drug class.

There are important caveats. The study is preclinical, conducted in organoids rather than in patients, and although organoids are among the most clinically predictive laboratory models available, they cannot fully reproduce the immune system, the bladder wall architecture or the complex urine environment that shapes drug activity in vivo. The number of organoid lines tested, six for the mitomycin C combinations, is modest, and the gemcitabine and epirubicin experiments were limited to a single line, so the generality of the synergy across the molecular diversity of bladder cancer remains to be established. Questions also remain about the optimal sequencing, dosing and delivery of ATR inhibitors in the bladder, and about whether systemic administration would be needed or whether the inhibitors could themselves be delivered intravesically to limit side effects.

Nevertheless, the study provides a compelling proof of principle that the DNA damage response is a druggable Achilles heel of non-muscle invasive bladder cancer, and it establishes patient-derived organoids as a practical platform for optimising intravesical combination therapies before they are tested in the clinic. The findings build on a growing body of evidence that ATR inhibition sensitises bladder tumours to DNA-targeted agents, including earlier work showing enhanced cisplatin and gemcitabine activity in bladder cancer cell lines and clinical trial data combining berzosertib with platinum chemotherapy in advanced urothelial carcinoma. If the synergy observed in these miniature tumours translates to patients, the humble bladder instillation, a treatment whose basic design has changed little in decades, could be transformed into a precision strike that leaves behind not just damaged cancer cells, but none at all.

Subject of Research: Combining ATR kinase inhibitors with intravesical chemotherapy to prevent recurrence in non-muscle invasive bladder cancer, tested in patient-derived organoids.

Article Title: ATR inhibitors synergise with mitomycin C to enhance cytotoxicity in patient-derived non-muscle invasive bladder cancer organoids

Article References: Zuidema, A., Nijland, L., van Megesen, K., Vosjan, M. M., Viergever, B. J., Kranenburg, O., & Meijer, R. P. (2026). ATR inhibitors synergise with mitomycin C to enhance cytotoxicity in patient-derived non-muscle invasive bladder cancer organoids. British Journal of Cancer. https://doi.org/10.1038/s41416-026-03581-0

Image Credits: AI Generated

DOI: 10.1038/s41416-026-03581-0

Keywords: bladder cancer, ATR inhibitors, mitomycin C, patient-derived organoids, DNA damage response, non-muscle invasive bladder cancer, berzosertib, ceralasertib, tuvusertib, intravesical chemotherapy, drug synergy, cancer recurrence

In current clinical practice, patients diagnosed annually with NMIBC—numbering over 60,000 in the U.S.—undergo an initial surgical procedure known as transurethral resection of bladder tumor (TURBT). This surgery removes visible tumors from the bladder lining. Subsequent treatment traditionally includes the administration of bacillus Calmette-Guérin (BCG), an immunotherapeutic agent delivered via bladder instillations. BCG therapy is designed to stimulate the patient’s immune system to target residual microscopic cancerous cells, thereby reducing the risk of recurrence. However, the clinical trajectory following TURBT and BCG varies widely between patients; some achieve durable remission with surgery alone, while others eventually relapse even after a full course of BCG. Until recently, clinicians have lacked robust tools to accurately predict individual patient outcomes in response to these treatments.

The implications of prognostic uncertainty are vast. BCG not only carries the burden of treatment-related adverse effects, including cystitis and systemic symptoms, but also suffers from a chronic global supply shortage that can limit patient access. For patients destined to experience relapse, delays in detecting recurrent disease until it becomes visible through conventional cystoscopy can result in missed opportunities for early and potentially more effective therapeutic intervention. This critical gap underlines the urgent need for better molecular diagnostics to stratify patients’ risk and customize treatment.

A transformative breakthrough emerged from an interdisciplinary collaboration involving the Stanford Departments of Urology and Radiation Oncology, together with the Stanford Cancer Institute. A landmark study, recently published in the prestigious journal Cell, reports the development of a novel noninvasive urine-based molecular diagnostic test capable of detecting minimal residual disease (MRD) after initial bladder cancer treatment. This assay leverages liquid biopsy techniques to identify tumor-derived DNA fragments shed into the urine, offering unprecedented sensitivity for surveillance and risk stratification.

Liquid biopsies are rapidly evolving as a front-line tool for cancer monitoring due to their ability to detect circulating tumor DNA with high precision from accessible biological fluids. In bladder cancer, urine represents a particularly advantageous medium, reflecting the tumor microenvironment directly. However, the Stanford researchers uncovered a significant biological confounder termed “clonal cystopoiesis,” wherein normal urothelial cells accumulate age-related, cancer-associated mutations that could mimic the presence of tumor DNA in urine samples. This phenomenon necessitated a refinement of existing molecular assays.

To address this issue, the Stanford team devised an innovative statistical approach designed to filter out these “background” mutations arising from non-malignant clonal expansions within the bladder epithelium. By computationally correcting for this field effect, the refined assay significantly enhanced the specificity and accuracy of urine tumor DNA detection. This breakthrough capability enabled the differentiation of patients who were effectively cured by surgery alone from those who required—and benefited from—adjuvant BCG immunotherapy.

When deployed prospectively in a cohort undergoing surgery followed by BCG, the enhanced liquid biopsy provided highly prognostic information. Detectable tumor DNA post-BCG treatment predicted nearly inevitable recurrence, whereas clearance of tumor DNA corresponded with favorable long-term outcomes. Remarkably, this molecular surveillance outperformed standard cystoscopy in some cases, identifying impending relapse even when cystoscopic evaluations appeared normal. This points to the potential for earlier, preclinical detection of recurrence, facilitating timely clinical interventions.

Delving deeper into molecular response dynamics, the study delineated three distinct treatment response groups based on tumor DNA kinetics throughout therapy: surgery responders, where tumor DNA vanished after surgical excision; BCG responders, characterized by residual tumor DNA post-surgery that diminished following immunotherapy; and non-responders, showing persistent or increasing tumor DNA despite BCG. This stratification underscores the assay’s utility not only in surveillance but also in mechanistically understanding tumor biology and treatment sensitivity.

Crucially, correcting for the clonal cystopoiesis field effect was indispensable for these insights. It eliminated false-positive signals stemming from mutation-rich benign urothelium that had hampered prior molecular detection efforts. The refined assay could now reliably attribute tumor DNA clearance or persistence to true cancer cell eradication or persistence, offering a molecular lens into the relative efficacy of surgery and immunotherapy for individual patients.

Molecular profiling further revealed differential biological drivers underlying response phenotypes. Tumors resistant to surgery exhibited gene expression patterns linked to proliferative and invasive phenotypes, suggesting intrinsic aggressive biology. In contrast, tumors amenable to BCG exhibited higher mutational burdens and active immune microenvironments, factors that render the cancer more immunologically visible—and thus susceptible to immunotherapy. These findings provide a biological rationale for tailored therapeutic approaches based on pre-treatment molecular tumor characterization.

This study’s implications extend profoundly into routine clinical practice. Presently, the standard approach prescribes BCG immunotherapy broadly to intermediate- and high-risk NMIBC patients after surgery because physicians cannot reliably identify those who are already molecularly cured by resection alone. The introduction of a field-effect-corrected urine assay offers the promise of personalized treatment decision-making: sparing patients without residual disease from unnecessary BCG, prioritizing limited BCG resources for those with confirmed molecular residual disease, and enabling early treatment escalation in high-risk patients to prevent progression to muscle-invasive disease.

Moreover, this approach could refine patient selection for clinical trials of novel therapeutics by identifying molecular subgroups most or least likely to respond to specific interventions. Reduction in false positives and non-invasive testing would also alleviate patient anxiety and decrease reliance on frequent, invasive cystoscopic exams, improving quality of life and healthcare resource utilization.

Beyond bladder cancer, the concept of age-related clonal mutation fields within epithelial tissues—the so-called field effect—has been documented in other organs including lung and colon. As liquid biopsy technologies become mainstream across diverse cancer types and sample types, integrating field-effect corrections to distinguish benign mutation backgrounds from true malignant signals will be critical for maximizing diagnostic accuracy and clinical utility.

If validated in larger, multi-institutional cohorts, this molecular urine test paradigm could revolutionize bladder cancer management, shifting the standard of care away from uniform protocols toward precision oncology models. Clinicians might soon rely on a simple urine sample to decide when to safely discontinue therapy or when to intensify treatment regimens, optimizing therapeutic impact while minimizing toxicity and costs. This represents a pivotal step forward in transforming bladder cancer care into a truly patient-specific discipline driven by cutting-edge molecular diagnostics.

Subject of Research: Cells
Article Title: Molecularly Informed Urine-Based Minimal Residual Disease Detection Transforms Bladder Cancer Management
News Publication Date: 19-Feb-2026
Web References: http://dx.doi.org/10.1016/j.cell.2025.12.054
Keywords: Urology, Cancer, Bladder Cancer, Non-Muscle Invasive Bladder Cancer, Liquid Biopsy, Tumor DNA, Bacillus Calmette-Guérin, Immunotherapy, Clonal Cystopoiesis, Molecular Diagnostics, Minimal Residual Disease, Personalized Medicine